表紙
市場調査レポート

マイクロRNA:miRNAベースのマイクロアレイ、診断、治療概要

MicroRNA: An Insight to miRNA-based Microarrays, Diagnostics and Therapeutics

発行 Insight Pharma Reports 商品コード 298557
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
マイクロRNA:miRNAベースのマイクロアレイ、診断、治療概要 MicroRNA: An Insight to miRNA-based Microarrays, Diagnostics and Therapeutics
出版日: 2014年04月28日 ページ情報: 英文 104 Pages
概要

マイクロRNA(miRNA)は、他のRNAコンポーネントと比べその独特な汎用性、安定性、特性によって研究がすすめられています。miRNAの非コード性と遺伝子発現への影響力によって、様々な疾患のためのバイオマーカーとしての利用が有望視されています。多くの学術研究機関がmiRNAのバリデーションにとどまらず多くの疾患におけるmiRNAの特定や分子作用の検証に取り組んでいます。

当レポートでは、マイクロRNA(miRNA)の特異性について検証するとともに、様々な研究を進める企業や学術研究機関の動向とその結果などをまとめ、概略下記の構成で取り上げております。

エグゼクティブサマリー

第1章 背景とイントロダクション

  • miRNAとは

第2章 miRNA:オリゴヌクレオチド合成とマイクロアレイ技術

  • miRNAの創出と応用
    • オリゴヌクレオチドのエンジニアリング
    • フォトリソグラフィー合成
    • miRNA拮抗薬のエンジニアリング
    • その他のエンジニアリング方法
  • Affymetrix:miRNAマイクロアレイとフォトリソグラフィー技術
    • 企業情報
    • GeneChip miRNA 4.0アレイ
    • フォトリソグラフィープロセスとアッセイの特徴
    • 改善領域と将来的期待
    • Dr. Johanne McGregorへのインタビュー
  • Exiqon:LNA技術を用いたmiRNA検出の改良
    • 研究の背景
    • バイオマーカーとしてのmiRNAの生物学
    • LNA技術
    • miRCURY LNA qPCRプラットフォーム:利点と市場の展望
    • Dr. Henrik M. Pfundheller へのインタビュー

第3章 miRNA:診断および治療への応用

  • 診断バイオマーカーとしてのmiRNAの使用
    • 診断への応用
  • Rosetta Genomics
    • 研究および企業情報
    • マイクロRNA診断プラットフォーム
    • 医療における進歩
    • 改善領域と限界
    • Ken Berlinへのインタビュー
  • DiamiR:miRNA神経診断
    • 企業情報
    • 汎用的スクリーニング検査と仕様
    • 利点と将来的展望
    • Kira Sheinermanへのインタビュー
  • Gensignia:miRNAの肺癌診断
    • 企業情報
    • miRNA信号分類による肺癌検査
    • 医療における進歩
    • Dr. Elisa Romeo へのインタビュー
  • エーザイ:miRNAの研究およびアルツハイマー診断
    • 企業情報
    • 循環バイオマーカーとしてのmiRNA
    • アルツハイマー病における研究
    • 競合戦略
    • 改善と限界
    • 将来的期待
    • Dr. Pavan Kumar へのインタビュー

第4章 学術分野におけるmiRNAの研究:標的、診断、エンドユーザーの展望

  • 学術分野におけるmiRNA:分子相互作用、診断および治療アプローチ、技術進歩の重要性の理解
  • Stony Brook University School of Medicine:結腸直腸癌におけるmiRNA
  • Grand Valley State University:パーキンソン病におけるmiRNA
  • 独立したmiRNA研究:腎臓学におけるmiRNAの役割
  • Van Andel Research Institute:miRNA創薬と技術の進歩

第5章 miRNAハイライト、課題、研究開発における進歩

  • 調査分析

参考

目次

New to Insight Pharma Reports is: MicroRNA: An Insight to miRNA-Based Microarrays, Diagnostics and Therapeutics. This report covers the specifics of microRNA (miRNA) as it is a relatively new space in heavy pursuit of research due to its versatility and stability, properties that are unique to miRNAs compared to other RNA components. miRNA's non-coding nature and ability to affect genetic expression make it a novel candidate for use as a biomarker for a variety of diseases. This prompted the pursuit of miRNA-based microarrays and diagnostics for the advancement in therapeutic development. Furthermore there are a number of academic laboratories not only validating miRNAs, but also identifying them in a number of diseases and examining their molecular actions in the presence of other molecules. This report is broken up into several parts, highlighting miRNA in several areas of research.

After covering background information, the second and third parts of this report expand upon several microarrays and diagnostics for specific analysis and therapeutic development. Several companies featured in this section include:

  • Affymetrix
  • Exiqon
  • Diamir
  • Rosetta Genomics
  • Eisai

Chapters within these sections feature company backgrounds and highlight proprietary technologies and platforms. Additionally, several advantages and limitations are also discussed. More significantly, these chapters are accompanied by interviews with company representatives, exclusively conducted for this report.

The fourth part of this report explores the academic, research and community perspectives. Although not developing diagnostics per se, academia is diligently investigating several aspects of miRNAs including their molecular properties for use as biomarkers for neurodegenerative diseases, diabetes, and even cancer. Universities and research institutes included in this area are:

  • Stony Brook University School of Medicine
  • Grand Valley State University
  • Van Andel Research Institute

Also included in these sections are interviews with experts in leading research from these universities. From a community perspective, Dr. Argyropoulos, a Medical Affairs Consultant, provides insight to the rapidly growing space and rising opportunities.

Finally, the report concludes with an in depth analysis of survey results. With 152 researchers, these results provide an overall perspective of the research community, capturing a number of miRNA applications, challenges afloat in the industry, and miRNA mechanisms of study.

Table of Contents

Executive Summary

Part I: Background and Introduction

CHAPTER 1: What is miRNA?

  • Transcription
  • Gene Expression

Part II: miRNA: Oligonucleotide Synthesis and Microarray Technologies

CHAPTER 2: miRNA Creation and Application

  • Engineering Oligonucleotides
  • Photolithographic Synthesis
  • Engineering miRNA Antagonists: OMe, MOE, and LNA
  • Other Engineering Methods: miRNA Mimicry

CHAPTER 3: Affymetrix: miRNA Microarrays and Photolithographic Technology

  • Company Bckground
  • GeneChip miRNA 4.0 Array
  • Photolithographic Process and Assay Features
    • Specificity and Sensitivity
    • Applications
  • Areas of Improvements and Future Expectations
  • Interview with Dr. Johanne McGregor
    • Company Background
    • GeneChip miRNA 4.0 Array
    • Targets and Applications
    • Technology
    • Challenges, Benefits, Improvements, and Future Expectations

CHAPTER 4: Exiqon: Improving miRNA Detection with LNA Technology

  • Research Background
  • The Biology of miRNAs as Biomarkers
  • Locked Nucleic Acid (LNA) Technology
  • miRCURY LNA qPCR Platform: Advantages and Market Outlook
  • Interview with Dr. Henrik M. Pfundheller
    • Research Background
    • Locked Nucleic Acid (LNA) Technology
    • microRNA qPCR Platform

Part III: miRNA: Diagnostic and Therapeutic Applications

CHAPTER 5: miRNA Use as Diagnostic Biomarkers

  • miRNA Diagnostic Applications

CHAPTER 6: Rosetta Genomics

  • Research and Company Background
  • microRNA Diagnostic Platforms
  • Advancements in Healthcare
  • Areas of Improvement and Limitations
  • Interview with Ken Berlin
    • Company Background
    • microRNA Diagnostic Platforms
    • Platform Specifications
    • Advancements in Healthcare
    • Improvements and Limitations

CHAPTER 7: DiamiR: miRNA Neuro-Diagnostics

  • Company Background
  • Universal Screening Test and Specifications
  • Advantages and Future Outlook
  • Interview with Kira Sheinerman
    • Company Background
    • Platforms and Specifications
    • Advantages, Limitations, and Future Expectations

CHAPTER 8: Gensignia: miRNA Lung Cancer Diagnostics

  • Company Background
  • miRNA Signature Classifier (MSC) Lung Cancer Test
  • Advancements in Healthcare
  • Interview with Dr. Elisa Romeo
    • Company Background
    • MSC Lung Cancer Test
    • Advancements in Healthcare

CHAPTER 9: Eisai: miRNA Research and Diagnostics for Alzheimer's Disease

  • Company Background
  • miRNAs As Circulating Biomarkers
  • Eisai's miRNA Research in Alzheimer's Disease
  • Competitive Strategies
  • Improvements and Limitations
  • Future Expectations
  • Interview with Dr. Pavan Kumar
    • Company Background
    • miRNA Research
    • Competitive Strategies
    • Advancements
    • Improvements
    • Future Expectations

Part IV: miRNA Research in Academia: Targets, Diagnostics, and End User Perspectives

CHAPTER 10: miRNAs in Academia: Understanding Molecular Interactions, Diagnostic and Therapeutic Approaches, and Significance of Technology Advancements

CHAPTER 11: Stony Brook University School of Medicine: miRNA in Colorectal Cancer

  • miRNA in Colorectal Cancer
    • p53 and miRNA in Colon Cancer
    • Epithelial-to-Mesenchymal Transition (EMT)
  • Diagnostic and Therapeutic Applications
  • Challenges Encountered and Areas of Improvement
  • Interview with Dr. Jingfang Ju
    • miRNA Research
    • miRNA Properties and Technologies
    • p53 and miRNA
    • Epithelial-to-Mesenchymal Transition (EMT)
    • Diagnostics and Therapeutic Applications
    • Challenges and Areas of Improvement
    • Future Applications

CHAPTER 12: Grand Valley State University: miRNA in Parkinson's Disease

  • Circulating miRNA as a Biomarker for Parkinson's Disease
  • Cerebral Spinal Fluid vs. Plasma
  • Advantages, Limitations, and Areas of Improvement
  • Interview with Dr. Sok Kean Khoo
    • Research Background
    • Competition
    • Methods and Properties
    • Areas of Improvement and Challenges

CHAPTER 13: Independent miRNA Research: The Role of miRNAs in Nephrology

  • Research Background
  • miRNA in Type 1 Diabetes and Diabetic Kidney Disease
  • Research Limitations, Challenges, and Areas of Improvement
  • Future Outlook, Applications and Growth
  • Interview with Dr. Christos Argyropoulos
    • Research Background
    • Challenges, Benefits and Areas of Improvement
    • Future Outlook and Industry Impact

CHAPTER 14: Van Andel Research Institute: miRNA Discoveries and Technology Advancement

  • Institution Background
  • Research Background
  • miRNA Properties and Discoveries
  • miRNA Tissue Slide-Based Assays
    • Advantages of miRNA Tissue Slide-Based Assays
    • Challenges and Limitations of miRNA Tissue Slide-Based Assays
    • Areas of Improvement
  • miRNA Market Outlook
  • Interview with Dr. Lorenzo Sempere
    • Research Background
    • miRNA Properties
    • Diagnostics and Therapeutics
    • Limitations and Advantages
    • Future Expectations

Part V: miRNA Highlights, Challenges, and Advances in R&D

CHAPTER 15: Survey Analysis

References

Back to Top